Leland Gershell
Stock Analyst at Oppenheimer
(4.58)
# 241
Out of 5,139 analysts
151
Total ratings
51.41%
Success rate
32.89%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiates: Outperform | $283 | $73.53 | +284.88% | 1 | Dec 23, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Outperform | $35 | $15.37 | +127.72% | 1 | Dec 23, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $22 → $54 | $24.35 | +121.77% | 6 | Dec 8, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $23 → $24 | $10.48 | +129.01% | 4 | Nov 14, 2025 | |
| ENGN enGene Holdings | Reiterates: Outperform | $30 → $33 | $9.31 | +254.46% | 3 | Nov 12, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $18 | $7.52 | +139.36% | 6 | Nov 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $33.26 | +8.24% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $55.99 | +55.38% | 8 | Sep 30, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $18.80 | +325.53% | 1 | Sep 3, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $42.48 | +158.95% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $76.26 | -20.01% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $359.27 | +36.39% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $7.39 | +170.64% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $101.63 | +8.24% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $215 → $224 | $205.83 | +8.83% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $18.80 | +64.89% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.22 | +136.97% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $800.01 | -11.50% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.55 | +181.69% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $54.59 | +79.52% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $44.10 | +17.91% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $192.97 | -23.82% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.69 | +1,758.74% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $26.27 | +101.75% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.98 | +201.51% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $3.31 | +150,957.40% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.01 | +399.00% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $5.13 | +289.86% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $22.70 | +27.75% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $15.06 | +132.40% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.30 | +3,211.26% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.95 | +2,002.39% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $2.05 | +534.15% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.69 | +3,152.03% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.05 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $31.76 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.96 | +5,124.66% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $14.78 | - | 5 | Mar 31, 2020 |
Spruce Biosciences
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $73.53
Upside: +284.88%
Aardvark Therapeutics
Dec 23, 2025
Initiates: Outperform
Price Target: $35
Current: $15.37
Upside: +127.72%
Capricor Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $24.35
Upside: +121.77%
Trevi Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $10.48
Upside: +129.01%
enGene Holdings
Nov 12, 2025
Reiterates: Outperform
Price Target: $30 → $33
Current: $9.31
Upside: +254.46%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $7.52
Upside: +139.36%
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $33.26
Upside: +8.24%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $55.99
Upside: +55.38%
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $18.80
Upside: +325.53%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $42.48
Upside: +158.95%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $76.26
Upside: -20.01%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $359.27
Upside: +36.39%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $7.39
Upside: +170.64%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $101.63
Upside: +8.24%
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $205.83
Upside: +8.83%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $18.80
Upside: +64.89%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $4.22
Upside: +136.97%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $800.01
Upside: -11.50%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $3.55
Upside: +181.69%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $54.59
Upside: +79.52%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $44.10
Upside: +17.91%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $192.97
Upside: -23.82%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.69
Upside: +1,758.74%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $26.27
Upside: +101.75%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.98
Upside: +201.51%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $3.31
Upside: +150,957.40%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.01
Upside: +399.00%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $5.13
Upside: +289.86%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $22.70
Upside: +27.75%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $15.06
Upside: +132.40%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.30
Upside: +3,211.26%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.95
Upside: +2,002.39%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $2.05
Upside: +534.15%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.69
Upside: +3,152.03%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.05
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $31.76
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $0.96
Upside: +5,124.66%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $14.78
Upside: -